CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of renal cell carcinoma.
  
  LEARNING OBJECTIVES

  • Evaluate recently presented data with adjuvant immune checkpoint inhibitor therapy for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the current role of this treatment strategy. 
  • Effectively apply evidence-based research findings and other clinical and biologic factors in the selection of first-line therapy for metastatic RCC (mRCC). 
  • Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel appropriate patients about the risks and benefits of these novel regimens.  
  • Review the biologic rationale underlying the investigation of anti-PD-1/anti-CTLA-4/multikinase inhibitor combination therapy as first-line treatment for mRCC, and appreciate emerging research findings documenting the effectiveness of this approach.  
  • Develop a rational therapeutic approach to the selection of treatment for advanced RCC in patients who experience disease progression on first-line treatment.  
  • Recognize side effects and toxicities commonly associated with approved and investigational therapeutic approaches, and use this information to develop supportive care plans for patients with RCC undergoing treatment with these agents and regimens.  
  • Recall available and emerging data with other novel and investigational agents and strategies currently in testing for RCC, and, where applicable, refer eligible patients for clinical trial participation. 

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Presentations Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Toni K Choueiri, MD
  Director, Lank Center for Genitourinary Oncology
  Department of Medical Oncology
  Dana-Farber Cancer Institute
  The Jerome and Nancy Kohlberg Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly, EMD Serono Inc, Exelixis Inc, Merck, Novartis, Pfizer Inc; Contracted Research: Exelixis Inc, GlaxoSmithKline.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by an educational grant from Exelixis Inc and Merck.
  
  Release date: November 2022
  Expiration date: November 2023